WO2006091722A3 - Alkyl-glycoside enhanced vaccination - Google Patents

Alkyl-glycoside enhanced vaccination Download PDF

Info

Publication number
WO2006091722A3
WO2006091722A3 PCT/US2006/006391 US2006006391W WO2006091722A3 WO 2006091722 A3 WO2006091722 A3 WO 2006091722A3 US 2006006391 W US2006006391 W US 2006006391W WO 2006091722 A3 WO2006091722 A3 WO 2006091722A3
Authority
WO
WIPO (PCT)
Prior art keywords
glycoside
alkyl
enhanced vaccination
vaccination
enhanced
Prior art date
Application number
PCT/US2006/006391
Other languages
French (fr)
Other versions
WO2006091722A2 (en
Inventor
John Jefferson Arnold
Chun-Ming Huang
Elias Meezan
Dennis J Pillion
De-Chu Tang
Original Assignee
Uab Research Foundation
John Jefferson Arnold
Chun-Ming Huang
Elias Meezan
Dennis J Pillion
De-Chu Tang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Research Foundation, John Jefferson Arnold, Chun-Ming Huang, Elias Meezan, Dennis J Pillion, De-Chu Tang filed Critical Uab Research Foundation
Priority to BRPI0607474A priority Critical patent/BRPI0607474A2/en
Priority to AU2006216671A priority patent/AU2006216671A1/en
Priority to CA 2598806 priority patent/CA2598806A1/en
Priority to JP2007557150A priority patent/JP2008531581A/en
Priority to MX2007010306A priority patent/MX2007010306A/en
Priority to EP20060735877 priority patent/EP1863511A2/en
Publication of WO2006091722A2 publication Critical patent/WO2006091722A2/en
Publication of WO2006091722A3 publication Critical patent/WO2006091722A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Described herein are methods for the noninvasive immunization of a subject that involve alkyl glycosides. Also described herein are compositions, kits, and devices for the noninvasive immunization of a subject.
PCT/US2006/006391 2005-02-23 2006-02-23 Alkyl-glycoside enhanced vaccination WO2006091722A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
BRPI0607474A BRPI0607474A2 (en) 2005-02-23 2006-02-23 glycoside-alkyl enriched vaccination
AU2006216671A AU2006216671A1 (en) 2005-02-23 2006-02-23 Alkyl-glycoside enhanced vaccination
CA 2598806 CA2598806A1 (en) 2005-02-23 2006-02-23 Alkyl-glycoside enhanced vaccination
JP2007557150A JP2008531581A (en) 2005-02-23 2006-02-23 Vaccination enhanced with alkyl-glycosides
MX2007010306A MX2007010306A (en) 2005-02-23 2006-02-23 Alkyl-glycoside enhanced vaccination.
EP20060735877 EP1863511A2 (en) 2005-02-23 2006-02-23 Alkyl-glycoside enhanced vaccination

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65531805P 2005-02-23 2005-02-23
US60/655,318 2005-02-23

Publications (2)

Publication Number Publication Date
WO2006091722A2 WO2006091722A2 (en) 2006-08-31
WO2006091722A3 true WO2006091722A3 (en) 2007-07-12

Family

ID=36928002

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/006391 WO2006091722A2 (en) 2005-02-23 2006-02-23 Alkyl-glycoside enhanced vaccination

Country Status (10)

Country Link
US (1) US7524510B2 (en)
EP (1) EP1863511A2 (en)
JP (1) JP2008531581A (en)
KR (1) KR20070120970A (en)
CN (1) CN101163494A (en)
AU (1) AU2006216671A1 (en)
BR (1) BRPI0607474A2 (en)
CA (1) CA2598806A1 (en)
MX (1) MX2007010306A (en)
WO (1) WO2006091722A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US8642564B2 (en) * 2004-08-25 2014-02-04 Aegis Therapeutics, Llc Compositions for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
CA2756690C (en) 2008-03-28 2016-08-16 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
CN102065900B (en) * 2008-06-23 2013-09-25 东亚荣养株式会社 Percutaneous absorption enhancer and transdermal preparation using the same
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
US9211282B2 (en) 2009-09-25 2015-12-15 Dr. Reddy's Laboratories Ltd. Formulations comprising triptan compounds
CN102933198B (en) * 2009-09-25 2015-10-07 雷迪博士实验室有限公司 Comprise the preparation of Qu Putan compound
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
US20110182976A1 (en) * 2010-01-28 2011-07-28 National Taiwan Ocean University Lipoplex-patch based dna vaccine
FR2959140A1 (en) * 2010-04-23 2011-10-28 Agro Ind Rech S Et Dev Ard FACILITATED PREPARATIONS OF VESICLES USING ALKYL POLY-PENTOSIDES AND USES THEREOF
EP2985027B1 (en) 2014-08-16 2021-03-31 Church & Dwight Co., Inc. Nasal composition comprising mixture of hyaluronic acids and saline solution
EP2985019B1 (en) * 2014-08-16 2021-10-20 Church & Dwight Co., Inc. Nasal composition having anti-viral properties
CN105342982B (en) * 2015-11-19 2018-08-28 上海现代药物制剂工程研究中心有限公司 Influenza vaccines immune formulation of nose administration and preparation method thereof
FR3065364A1 (en) * 2017-04-19 2018-10-26 Dental Monitoring DENTAL SHOOTING DEVICE

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3608030A (en) 1969-05-21 1971-09-21 Howard Tint Method of preparing a tablet dosage-form for the immunization of the intestinal tract with live virus preparations
US3837340A (en) 1971-10-20 1974-09-24 Lilly Co Eli Device for administering immunication against virus
US3906092A (en) 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
US3950512A (en) 1972-07-25 1976-04-13 Pitman-Moore, Inc. Animal vaccines
US3962424A (en) 1974-01-31 1976-06-08 Recherche Et Industrie Therapeutiques (R.I.T.) Live brovine adenovirus vaccines, preparation thereof and method of vaccination using them
CH588887A5 (en) 1974-07-19 1977-06-15 Battelle Memorial Institute
US3937412A (en) 1975-04-23 1976-02-10 Damour Lawrence R Expanding outer sleeve for a mandrel or chuck
US4405616A (en) 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4241046A (en) 1978-11-30 1980-12-23 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS562353A (en) * 1979-06-20 1981-01-12 Ricoh Co Ltd Novel disazo compound and its preparation
US5866383A (en) 1982-11-30 1999-02-02 The United States Of America As Represented By The Department Of Health And Human Services In vitro ligation of foreign DNA into large eukaryotic viruses
GB8303994D0 (en) 1983-02-14 1983-03-16 Council Of Governors Of United Antigenic materials
US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4623541A (en) 1984-06-26 1986-11-18 Candian Patents And Development Limited Production of purified porcine immunoglobulins
US4623544A (en) 1984-08-03 1986-11-18 Highnote Sidney T Constant temperature fryer/cooker assembly
US4738846A (en) 1984-08-30 1988-04-19 The Salk Institute For Biological Studies Vaccine for vesicular stomatitis virus
DK17685D0 (en) 1985-01-14 1985-01-14 Hans Goeran Magnusson glycoside
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5206163A (en) 1985-07-08 1993-04-27 Chiron Corporation DNA encoding bovine diarrhea virus protein
DE3674299D1 (en) 1985-08-01 1990-10-25 Harry Frankel SPRAYING VACCINATION DEVICE.
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4806350A (en) 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
US4775630A (en) 1986-08-15 1988-10-04 Vanderbilt University Transcriptional control element adapted for regulation of gene expression in animal cells
US4929442A (en) 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US4863970A (en) 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
NZ219515A (en) 1987-02-10 1989-09-27 Wellcome Found Fusion proteins comprising influenza virus ha and a nonnatural antigenic epitope
US4944942A (en) 1987-08-27 1990-07-31 Mobay Corporation Intranasal vaccination of horses with inactivated microorganisms or antigenic material
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5182258A (en) 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5616326A (en) 1990-01-25 1997-04-01 The University Court Of The University Of Glasgow Recombinant canine adenovirus 2 (CAV-2)
US5369095A (en) 1990-02-14 1994-11-29 Alcon Laboratories, Inc. Compositions and method comprising substituted glycosides as mucus membrane permeation enhancers
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5665362A (en) 1990-09-25 1997-09-09 Cantab Pharmaceuticals Research Limited Viral vaccines
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
CA2097830C (en) 1990-12-04 2000-02-01 Stephen G. Newman Spray-dried antigenic products and method of preparation
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
DE4119856A1 (en) 1991-06-17 1992-12-24 Hoechst Ag N-ACYL-S- (2-HYDROXYALKYL) -CYSTEINS, THE PRODUCTION AND USE THEREOF AS INTERMEDIATE PRODUCTS FOR THE PRODUCTION OF SYNTHETIC IMMUNE ADJUVANTS AND SYNTHETIC VACCINANTS
US5718902A (en) 1991-06-17 1998-02-17 The Regents Of The University Of California Double recombinant vaccinia virus vaccines
US5874279A (en) 1991-07-18 1999-02-23 Syntro Corporation Recombinant infectious bovine rhinotracheitis virus
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5645834A (en) 1992-08-28 1997-07-08 Immuno-Dynamics, Inc. Method and product for treating failure of passive transfer and improving milk production in bovine species
HU221308B1 (en) 1992-10-26 2002-09-28 Sanol Arznei Schwarz Gmbh Process for producing microcapsules
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
WO1994015640A1 (en) 1993-01-12 1994-07-21 Anthony George Gristina Methods and compositions for the direct concentrated delivery of passive immunity
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5384128A (en) 1993-03-02 1995-01-24 University Of Alabama Research Foundation Method of and compounds for treatment for cystic fibrosis
EP0692972B2 (en) 1993-04-02 2012-03-21 AntiCancer, Inc. Method for delivering beneficial compositions to hair follicles
AU7097494A (en) 1993-06-01 1994-12-20 Targeted Genetics Corporation Envelope fusion vectors for use in gene delivery
US5834256A (en) 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US6632456B1 (en) * 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
IS1796B (en) * 1993-06-24 2001-12-31 Ab Astra Inhaled polypeptide formulation composition which also contains an enhancer compound
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5543328A (en) 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US5820868A (en) 1993-12-09 1998-10-13 Veterinary Infectious Disease Organization Recombinant protein production in bovine adenovirus expression vector system
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
US5635380A (en) 1994-01-18 1997-06-03 Vanderbilt University Enhancement of nucleic acid transfer by coupling virus to nucleic acid via lipids
FR2716682B1 (en) 1994-01-28 1996-04-26 Centre Nat Rech Scient Process for the preparation of recombinant adeno-associated viruses (AAV) and uses thereof.
US5731172A (en) 1994-03-09 1998-03-24 Sumitomo Pharmaceuticals Company, Ltd. Recombinant adenovirus and process for producing the same
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
JP2930526B2 (en) 1994-05-31 1999-08-03 株式会社キートロン Injector type atomizer
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
JP4216350B2 (en) 1994-09-19 2009-01-28 大日本住友製薬株式会社 Recombinant DNA viral vector for animal cell infection
US5552309A (en) 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
US5880102A (en) * 1995-01-17 1999-03-09 Duke University Adenoviral vector system
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US5872154A (en) 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
JP3770333B2 (en) 1995-03-15 2006-04-26 大日本住友製薬株式会社 Recombinant DNA virus and method for producing the same
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
AU5543196A (en) 1995-04-12 1996-10-30 Robert B. Hopp Skin patch for use in contact immunotherapy
US5705151A (en) 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5698202A (en) 1995-06-05 1997-12-16 The Wistar Institute Of Anatomy & Biology Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
US5763270A (en) 1995-06-07 1998-06-09 Genemedicine, Inc. Plasmid for delivery of nucleic acids to cells and methods of use
US5824538A (en) 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
CA2177085C (en) * 1996-04-26 2007-08-14 National Research Council Of Canada Adenovirus e1-complementing cell lines
US5731181A (en) 1996-06-17 1998-03-24 Thomas Jefferson University Chimeric mutational vectors having non-natural nucleotides
US5707812A (en) 1996-08-06 1998-01-13 Vical Incorporated Purification of plasmid DNA during column chromatography
US5830177A (en) 1996-11-22 1998-11-03 Anticancer, Inc. Skin vibration method for topical targeted delivery of beneficial agents into hair follicles
US5830730A (en) 1997-05-08 1998-11-03 The Regents Of The University Of California Enhanced adenovirus-assisted transfection composition and method
US6716823B1 (en) * 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US6348450B1 (en) * 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
GB9720465D0 (en) * 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
US20020169138A1 (en) * 1997-10-24 2002-11-14 Southern Research Institute Delivery vehicles for bioactive agents and uses thereof
US6087341A (en) * 1998-02-12 2000-07-11 The Board Of Trustees Of The Leland Standford Junior University Introduction of nucleic acid into skin cells by topical application
US6100614A (en) * 1999-01-12 2000-08-08 A. O. Smith Corporation Electric motor with spring clip for strain relief
US20030157113A1 (en) * 1999-12-28 2003-08-21 Terman David S. Compositions and methods for treatment of neoplastic disease
IL155073A0 (en) * 2000-10-02 2003-10-31 Glaxosmithkline Biolog Sa Split enveloped virus preparation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BABIUK S. ET AL.: "Cutaneous vaccination: the skin as an immunologically action tissue and the challenge of antigen delivery", J. CONTROLLED RELEASE, vol. 66, 2000, pages 199 - 214, XP004193068 *
CHOI Y.H. ET AL.: "Lactose-Poly(ethylene Glycol)-Grafted Poly-L-Lysine as Hepatoma Cell-Targeted Gene Carrier", BIOCONJUGATE CHEM., vol. 9, 1998, pages 708 - 718, XP000786594 *
TANG D. ET AL.: "Vaccination onto bare skin", NATURE, vol. 388, 1997, pages 729 - 730, XP002110051 *

Also Published As

Publication number Publication date
US7524510B2 (en) 2009-04-28
KR20070120970A (en) 2007-12-26
MX2007010306A (en) 2007-09-26
EP1863511A2 (en) 2007-12-12
WO2006091722A2 (en) 2006-08-31
JP2008531581A (en) 2008-08-14
CN101163494A (en) 2008-04-16
BRPI0607474A2 (en) 2016-11-01
CA2598806A1 (en) 2006-08-31
US20060233761A1 (en) 2006-10-19
AU2006216671A1 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
WO2006091722A3 (en) Alkyl-glycoside enhanced vaccination
WO2008100805A3 (en) Anti-robo4 antibodies and uses therefor
WO2007133290A3 (en) Anti-ox40l antibodies and methods using same
WO2006083936A3 (en) Anti-ephb2 antibodies and methods using same
WO2007130697A8 (en) Anti-ephb4 antibodies and methods using same
WO2004064595A3 (en) Multivalent constructs for therapeutic and diagnostic applications
WO2008060705A3 (en) Anti-dll4 antibodies and methods using same
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
WO2005082020A3 (en) Flavivirus vaccines
WO2008052187A3 (en) Antibodies and immunoconjugates and uses therefor
WO2007120334A8 (en) Methods and compositions for targeting polyubiquitin
WO2006133879A3 (en) Vaccines for immunization against helicobacter
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
WO2008054676A3 (en) Medical devices and methods of using the same
WO2006124713A3 (en) 4-biarylyl-1-phenylazetidin-2-ones
WO2008051197A3 (en) Small-molecule botulinum toxin inhibitors
EP1812054A4 (en) Methods and compositions for immunizing against pseudomonas infection
WO2008025015A3 (en) Epitope-protein scaffolds and their use
WO2008112192A3 (en) Epha3 antibodies for the treatment of solid tumors
WO2008027600A3 (en) Imatinib compositions
WO2008017074A3 (en) Dyes and precursors and conjugates thereof
WO2007127506A3 (en) Anti-ephrinb2 antibodies and methods using same
WO2007144779A3 (en) Compositions comprising porphyra and methods of making and using thereof
WO2006124630A3 (en) Compositions and methods for enhancing the efficacy of vaccines
WO2005074645A3 (en) Methods and compositions for modulating angiogenesis

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680013677.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007557150

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2598806

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/010306

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006216671

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006735877

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006216671

Country of ref document: AU

Date of ref document: 20060223

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020077021950

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0607474

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20070823